Skip to main content
DNTH logo

DNTH · Dianthus Therapeutics, Inc. /DE/

Track DNTH — free
$106.15 -0.47 (-0.44%)
Market Cap
$5.99B
Shares
55.93M

DNTH metrics

57 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$106.62
Market cap
$5.99B

Price action

19 metrics
Price change (1W)
-4.9%
Price change (30D)
+0.6%
Price change (3M)
+30.7%
Price change (6M)
+92.5%
Price change (YTD)
+158.7%
Price change (1Y)
+352.4%
Trailing year
Price change (5Y)
+2.0%
52-week high
$115.96
52-week low
$23.85
Change from 52-week high
-8.1%
Change from 52-week low
+347.0%
Annualized volatility
65.6%
Beta
0.9
RSI (14D)
47.6
Price vs SMA 50
+2.3%
Price vs SMA 200
+42.2%
Avg volume (3M)
1.04M
Relative volume
0.6
Average dollar volume
$99.46M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
55.93M

Valuation

12 metrics
P / E (TTM)
Trailing earnings
PEG ratio
EV / revenue
EV / EBITDA
EV / EBIT
P / sales
2,941.0×
reciprocal yield 0.0%
P / book
5.1
reciprocal yield 19.6%
FCF yield
TTM · current market cap
Buyback yield
P / FCF
P / operating cash flow
Earnings yield
-3.2%

Historical valuation

8 metrics
P / E historical average (3Y)
P / E historical average (5Y)
EV / revenue historical average (3Y)
EV / revenue historical average (5Y)
EV / EBIT historical average (3Y)
EV / EBIT historical average (5Y)
EV / EBITDA historical average (3Y)
EV / EBITDA historical average (5Y)

Dividends & buybacks

7 metrics
Dividend yield
Trailing 12 months
Payout ratio
Shareholder yield
Dividend / share (TTM)
Dividend growth YoY
Dividend growth streak
Last ex-dividend

Earnings calendar

2 metrics
Next earnings
Last earnings
2026-03-09

Profitability

9 metrics
Gross margin
Operating margin
-8,739.3%
Trailing 12 months
Net margin
-7,973.3%
Gross profit (TTM)
Operating profit (TTM)
−$217.84M
Net income (TTM)
−$192.25M
Trailing 12 months
Diluted EPS (TTM)
$-4.25
FCF margin
Effective tax rate

Per share

11 metrics
Revenue per diluted share (TTM)
Gross profit per diluted share (TTM)
Operating profit per diluted share (TTM)
EBITDA per diluted share (TTM)
Net income per diluted share (TTM)
Operating cash flow per diluted share (TTM)
Free cash flow per diluted share (TTM)
Capital expenditures per diluted share (TTM)
R&D per diluted share (TTM)
Stock compensation per diluted share (TTM)
Book value per share
$-17.91

Growth

11 metrics
Revenue growth YoY
-78.6%
Year over year
Net income growth YoY
Revenue (TTM)
$2.04M
Trailing 12 months
EPS growth YoY
Shares change YoY
+56.4%
Year over year · more shares
Revenue CAGR (3Y)
-31.8%
Revenue CAGR (5Y)
EPS CAGR (3Y)
EPS CAGR (5Y)
FCF CAGR (3Y)
FCF CAGR (5Y)

Quality

14 metrics
Return on equity
-16.4%
Return on assets
-15.8%
Debt / equity
Current ratio
26.1
EBITDA (TTM)
−$5.89M
Free cash flow (TTM)
Quick ratio
26.1
Interest coverage
Net debt / EBITDA
Return on invested capital
Trailing 12 months
Net cash
$886.81M
Latest balance sheet
Cash & equivalents
$110.55M
Total assets
$1.21B
Total debt

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$155.38M
Capital expenditures (TTM)
$403,000
R&D (TTM)
$175.60M
SG&A (TTM)
Stock compensation (TTM)
$34.27M
R&D / revenue
Stock compensation / revenue

Ownership (13F)

3 metrics
13F filers
272
13F filer change QoQ
+29
Institutional ownership
118.4%

Short interest

3 metrics
Short interest
15.1%
Latest settlement · 11.5 days to cover
Days to cover
11.5d
Short-squeeze score
72 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$27.21M
Insider-sentiment score

Risk flags

1 metrics
Going concern
Key facts CIK 1690585 CUSIP 252828108 13F (30d) 244 filings 241 filers Visit website Investor relations